Article

RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSION

2021-12-21

Abstract excerpt

<h4>ABSTRACT</h4> Several Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralising monoclonal antibodies (mAbs) have received emergency use authorisation by regulatory agencies for treatment and prevention of Coronavirus Disease 2019 (COVID-19), including in patients at risk for progression to severe disease. Here we report the persistence of viable SARS-CoV-2 in patients treated with sotrovimab a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 452cd985-b741-531e-822a-0f8e27e14c4c
DOI: 10.1101/2021.12.18.21267628

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSIONDOI 10.1101/2021.12.18.21267628Read

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.Semantic proximity Read

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsSemantic proximity Read

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read

Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity Read

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity Read

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read

Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.Semantic proximity Read

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.Semantic proximity Read

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatmentSemantic proximity Read